Skip to content

Immix Biopharma, Inc. IMMX Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)

Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s total cash, cash equivalents, and restricted cash (inclusive).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
Immix Biopharma, Inc. (IMMX) reported total cash, cash equivalents, and restricted cash (inclusive) of $79.25M in Q1 2026.
How has Immix Biopharma, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
Immix Biopharma, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) increased by 397.8% year-over-year, from $15.92M to $79.25M.
What is the long-term trend for Immix Biopharma, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) has grown at a 199.3% compound annual growth rate (CAGR), from $391.09K to $93.93M.
What does total cash, cash equivalents, and restricted cash (inclusive) mean?
This metric aggregates all highly liquid assets, including cash, cash equivalents, and restricted cash, regardless of whether they are held for operations or specific contractual obligations. It serves as the primary measure of a company's immediate liquidity and its ability to fund ongoing research and development activities. Monitoring this balance is essential for assessing the company's runway in a clinical-stage environment.